Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01767454
Title Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors GlaxoSmithKline



Dabrafenib + Ipilimumab + Trametinib

Dabrafenib + Ipilimumab

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST